Cameron MacLeod @c_9@mstdn.ca
Public

Umm, this is big COVID prevention news. Nobody tell RFK Jr.

Original bsky thread at link below.

“THIS IS HUGE! Researchers at Stanford University have developed a dual-antibody treatment that remains effective against ALL SARS-CoV-2 variants by targeting a less-mutable part of the virus. This breakthrough could lead to longer-lasting therapies that OUTPACE viral evolution.

The study has been published in Science. YES, it is PEER-REVIEWED. science.org/doi/10.1126/scitra “

🧵 bsky.app/profile/sailorrooscou

Abstract The ongoing emergence of severe acute respiratory syndrome coronavirus (SARS-CoV-2) variants of concern that reduce the effectiveness of antibody therapeutics necessitates development of next-generation antibody modalities that are resilient to viral evolution. Here, we characterized amino-terminal domain (NTD) - and receptor binding domain (RBD)-specific monoclonal antibodies previously isolated from COVID-19 convalescent donors for their activity against emergent SARS-CoV-2 VOCs. Among these, NTD-specific antibody C1596 displayed the greatest breadth of binding to VOCs, with cryo-electron microscopy structural analysis revealing recognition of a distinct NTD epitope outside of the site i antigenic supersite. Given C1596's favorable binding profile, we designed a series of bispecific antibodies (bsAbs), termed CoV2-biRNs, that featured both NTD & RBD specificities. Two of the C1596-inclusive bsAbs, CoV2-biRN5 and CoV2-biRN7, retained potent in vitro neutralization activity against all Omicron variants tested, including XBB.1.5, BA.2.86, and JN.1, contrasting the diminished potency of parental antibodies delivered as monotherapies or as a cocktail. Furthermore, prophylactic delivery of CoV2-biRN5 reduced viral load within the lungs of K18-hACE2 mice after challenge with SARS-CoV-2 XBB.1.5. In conclusion, NTD-RBD bsAbs offer promising potential for the design of resilient, next-generation antibody therapeutics against SARS-CoV-2 VOCs.Diagram showing NTD Antibody + RBD Antibody leading to a combination labeled CoV2-biRNMore realistic diagram rather than the previous geometric one, showing NTD and RBD before and after the new approach has attached itself.
0
0
0

If you have a fediverse account, you can quote this note from your own instance. Search https://mstdn.ca/users/c_9/statuses/114135425810803216 on your instance and quote it. (Note that quoting is not supported in Mastodon.)